California's Ligand Teams Up With Chinese Drug Player For Hep B Treatment Aimed At 80 Million People In China
This article was originally published in PharmAsia News
Executive Summary
BEIJING - La Jolla, California-based Ligand Pharmaceuticals is creating an alliance with Chiva Pharmaceuticals centered on a licensing agreement that will give Chiva the right to develop anti-hepatitis medicines in China, where hepatitis B has already infected more than 80 million people, and access to Ligand's technology to develop products globally for other liver ailments
You may also be interested in...
Spectacular Market Launches Key To Enduring Success Of Brands In APAC - IMS Health
MUMBAI - Following studies on the launch of patented brands in the Asia-Pacific market, IMS Health said less than 20 percent of brands perform well if they do not strike significant success within the first six months of their launches
Genzyme, Alcon Deals Throw Spotlight on Earn-Outs, Now Commonplace in Private Deals
Should Genzyme Corp. succumb to the advances of Sanofi-Aventis, contingent value rights (CVRs, or earn-out payments) will likely play a significant part in bridging the valuation gap that now exists between those companies.
Pfizer Forges New Research Partnership In China Aimed In Part At Fighting A Leading Cause Of Death
BEIJING - Still expanding globally after engineering the pharmaceutical world's most massive merger of the year, the titan-like Pfizer is partnering with the comparatively tiny contract research organization Crown Bioscience to develop new medicines aimed at fighting cancers that are prevalent in Asia, according to a leading Pfizer Asia executive